NIH R01 · 2024
SUMMARY Tuberculosis (TB) is the leading cause of death from a single infection worldwide, with an annual death toll of over 1.6 million lives. TB is curable and drug regimens can be above 90% effective if completed but are long and toxic leading to noncompliance and emergence of resistance. New treatment options relying on novel and unexplored targets are scarce. The BPaL regimen recently approved by the FDA features, for the first time in many decades, drugs against new Mtb targets (ATP synthase) and with novel mode of action (nitroimidazoles). Nevertheless, more inhibitors against previously unexplored targets are urgently needed to sustain the TB drug pipeline, as resistance is already…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.